UMIN-CTR History

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Unique ID issued by UMIN UMIN000009155
Receipt No. R000010735
Scientific Title Tamoxifen Response by CYP2D6 Genotype-Based Treatment in Patients with Metastatic or Recurrent Breast Cancer
Date of disclosure of the study information 2012/10/20
Last modified on 2018/06/19 11:48:05

No. Disposal Last modified on Item of update
1 Insert 2012/10/20 14:15:20
2 Update 2012/12/26 16:28:24 Recruitment status
Anticipated trial start date
3 Update 2012/12/26 17:03:50 Anticipated trial start date
4 Update 2013/12/26 20:06:58 TEL
Email
Address
TEL
Homepage URL
Email
5 Update 2014/09/02 13:16:51 Region
6 Update 2014/09/02 13:30:50 Key secondary outcomes
Key secondary outcomes
7 Update 2014/09/02 14:16:01 Key inclusion criteria
Key exclusion criteria
8 Update 2014/09/02 14:30:58 Key secondary outcomes
9 Update 2014/09/02 14:32:54 Key inclusion criteria
10 Update 2015/04/21 11:50:40 Organization
Organization
11 Update 2015/09/28 18:52:01 Last name of contact person
Last name of contact person
Organization
Organization
Division name
Division name
Address
Address
TEL
Homepage URL
Email
Institute
Institute
Organization
Organization
Category of Funding Organization
Name of secondary funder(s)
Name of secondary funder(s)
12 Update 2016/05/17 12:36:08 Randomization unit
Interventions/Control_1
Interventions/Control_1
Interventions/Control_2
Interventions/Control_2
Interventions/Control_3
Interventions/Control_3
Target sample size
13 Update 2016/05/17 12:40:32 Organization
Name of primary sponsor
Organization
Organization
Category of Funding Organization
14 Update 2016/08/03 10:08:38 Recruitment status
Last follow-up date
15 Update 2017/04/24 09:02:33 Anticipated trial start date
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
16 Update 2018/05/07 11:14:03 Recruitment status
17 Update 2018/06/19 11:48:06 Publication of results
URL related to results and publications


Contact us.